Consensus Incyte Corporation Sao Paulo

Stocks

I1NC34

BRI1NCBDR004

Pharmaceuticals

Market Closed - Sao Paulo 11:37:56 2026-10-26 am EDT			5-day change	1st Jan Change
310.17 ^BRL	+7.60%		+7.60%	+11.93%

05:21pm	Incyte Corporation - Special Call
03:38am	Genmab, Incyte Sign Colorectal Cancer Trial Collaboration for Colorectal Cancer Treatment	MT

4ad7251695b99ffbd.MG1GhspjGgEBgjoWV1vjoiJKkZLkIJEWuOjqvhvl2Kg.YVsvzpUOUGBjyVRwJB-31xIuwsGxeekl-pm98WyC7eF-JxLVqAsqXlm3aw~7b82f029a8398b60082f8ef01bb0bcc5

Analysts' recommendations: Incyte Corporation

Oct. 22	Leerink Partners Adjusts Price Target on Incyte to $154 From $155	MT
Oct. 21	TD Cowen Adjusts Price Target on Incyte to $140 From $138	MT
Oct. 15	Goldman Sachs Adjusts Price Target on Incyte to $117 From $118	MT
Oct. 14	Truist Raises Price Target on Incyte to $115 From $105, Keeps Hold Rating	MT
Oct. 08	RBC Lifts Price Target on Incyte to $114 From $109, Keeps Sector Perform Rating	MT
Oct. 05	Stifel Adjusts Price Target on Incyte to $157 From $145, Keeps Buy Rating	MT
Oct. 01	Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating	MT
Sep. 28	HC Wainwright Adjusts Price Target on Incyte to $152 From $150, Maintains Buy Rating	MT
Sep. 28	JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating	MT
Aug. 20	Canaccord Genuity Initiates Incyte at Buy With $152 Price Target	MT
Aug. 17	Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating	MT
Aug. 13	Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating	MT
Aug. 03	Mizuho Adjusts Price Target on Incyte to $137 From $121	MT
Aug. 03	Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating	MT
Jul. 31	Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating	MT
Jul. 30	JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating	MT
Jul. 29	Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says	MT
Jul. 29	TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating	MT
Jul. 29	Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating	MT
Jul. 29	Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating	MT
Jul. 29	BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating	MT
Jul. 29	Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating	MT
Jul. 29	Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating	MT
Jul. 29	HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating	MT
Jul. 29	Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating	MT

More recommendations

Biopharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
INCYTE CORPORATION	-	-	-	-
ELI LILLY AND COMPANY				+4.56%
JOHNSON & JOHNSON				+5.91%
ABBVIE INC.				-0.3%
ROCHE HOLDING AG				-1.16%
MERCK & CO., INC.				+9.97%
NOVARTIS AG				-3.36%
ASTRAZENECA PLC				+22.49%
AMGEN INC.				-9.55%
GILEAD SCIENCES, INC.				+2.66%
Average				+3.47%
Weighted average by Cap.				+3.79%